Anti Cd 20 Ocrevus denied for missing prior authorization by Humana?

Humana's specific coverage criteria for anti cd20 ocrevus are defined in its own published medical/coverage policy and the FDA-approved prescribing label. A successful appeal documents that your medical records satisfy each criterion those sources list — confirmed diagnosis, any required prior treatments (with dates and outcomes), and clinical severity. If the exact criteria weren't included with your denial, request them in writing; your appeal then maps each requirement to the matching fact in your chart.

## Why Humana Requires Prior Authorization for Ocrelizumab

Ocrelizumab (Ocrevus) is a high-cost specialty biologic administered by intravenous infusion. Humana requires prior authorization for this drug because its cost and clinical profile place it in a tier subject to utilization management review. A prior-auth-required denial means either that the claim was submitted before authorization was in place, or that an authorization request was submitted and denied on clinical grounds. These are two different problems with different solutions — it is important to determine which applies to your situation.

## Why This Denial Is Appealable

If the denial is purely administrative — a claim submitted without an active PA — the path forward is to obtain or retroactively request the authorization, not to file a clinical appeal. If the PA was requested and denied on clinical grounds, that is a medical-necessity determination and is subject to full appeal under federal law. In either case, you have rights to a review, and Humana must explain the specific basis for any clinical denial in writing.

## Your Federal Appeal Rights

• Internal appeal: ERISA §503 and ACA §2719 entitle you to a full-and-fair internal review. The deadline for filing is stated in your denial letter.
• External review: After exhausting internal remedies, an independent external review is available under ACA §2719, generally within approximately four months of final internal denial.
• Expedited track: Patients currently receiving ocrelizumab infusions who face interruption should request expedited review immediately; decisions are typically required within 72 hours.
• Peer-to-peer review: Before filing a formal appeal, many Humana clinical denials can be reconsidered through a peer-to-peer call between your neurologist and Humana's medical director. Ask whether this option is available; it is often faster than the formal appeal process.

## Documentation to Gather

1. Humana's PA criteria for ocrelizumab — request the current written criteria so the prescriber's letter addresses each item directly. 2. Neurologist's medical-necessity letter answering each PA criterion in sequence, using language that mirrors Humana's policy where possible. 3. Diagnosis records — MRI reports, clinical notes, and diagnostic workup confirming the MS diagnosis and classification. 4. Prior disease-modifying therapy history — a complete, dated log of every MS therapy previously tried, with documented start dates, end dates, and reasons for stopping. 5. Infusion and prescription history — if ocrelizumab has been previously authorized and administered, include that authorization history as evidence of prior plan-accepted medical necessity.

## Criteria-Mapping Approach

Obtain Humana's written PA criteria and structure the appeal package so that every criterion is answered explicitly. Build a table: left column lists each criterion verbatim from the policy; right column cites the specific chart note, date, lab result, or prior-treatment record that satisfies it. This format signals to the reviewer that no criterion has been overlooked and reduces the risk of a second denial citing a different unmet requirement.

## Next Step

Determine first whether a PA was ever submitted for this claim. If not, contact Humana to ask about retroactive authorization. If a PA was submitted and denied, request the written denial with the specific clinical criteria that were not met — that document is the foundation of the appeal.